Core Viewpoint - The trend of A-share companies seeking to list in Hong Kong continues, with a significant number of companies announcing plans to do so in September 2023 [1] Group 1: A-share Companies Going Public in Hong Kong - As of September 30, three A-share listed companies, namely XinNuoWei, Kexing Pharmaceutical, and KOTAI Power, announced plans to list in Hong Kong [1] - In total, 25 A-share listed companies have announced plans to list in Hong Kong since the beginning of September 2023 [1] - As of October 2, there are 76 A-share listed companies that have submitted listing materials to the Hong Kong Stock Exchange and are awaiting hearings [1] Group 2: Industry Distribution - The A-share companies that have submitted applications for listing in Hong Kong cover various industries, including pharmaceuticals, telecommunications, food and beverages, automotive, and machinery [1] - Notable companies from multiple sectors are among those seeking to list in Hong Kong [1]

Key Points - Fengshan Group clarified that its sales do not involve solid-state battery electrolyte materials [1] - Zhiwei Co., Ltd. plans to invest approximately 1.5 billion yuan in the construction of high-end cast steel pump and valve components manufacturing project [1] - Tianyong Intelligent won a bid for a 58.8 million yuan DHE high-efficiency platform production line engine assembly line project [1] - Hanwei Technology intends to sell 65% of its stake in Hanwei Zhiyuan [1] - Huaxin Environmental plans to repurchase shares worth between 40 million to 80 million yuan [1] - Xin Nuo Wei is planning to issue E-shares and list on the Hong Kong Stock Exchange [1] - Shareholders of Run Da Medical, Zhu Wenyi and Liu Hui, plan to reduce their holdings by no more than 2.99% [1] - Feng Assistant intends to raise no more than 984 million yuan through a private placement to actual controllers [1] - Jiaotong Sino's chairman Li Wei has been placed under detention [1] Investment Projects - Nong Shang Environment's subsidiary plans to invest in the construction of intelligent computing center infrastructure [1] - Sai En Si (Fujian Longli Chemical) plans to invest no more than 300 million yuan in the expansion of the selection agent project [1] - Bin Hua Co. intends to invest 1.421 billion yuan in the construction of an integrated source network load storage project [1] Contracts and Acquisitions - Zhong Wu Drone signed a major contract worth 615 million yuan [1] - Xin Nuo Wei plans to acquire a 29% stake in Ju Shi Bio [1] - Huaheng Biological submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [1] - Kete Power plans to issue shares overseas (H-shares) and apply for listing on the Hong Kong Stock Exchange [1]

Core Viewpoint - The company, Sinopharm, is advancing its global strategy by planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international competitiveness and support the development of its pharmaceutical business [3]. Group 1 - The company is currently in discussions with relevant intermediaries regarding the issuance of H-shares and the listing process [1]. - The board of directors and the supervisory board have approved the proposal to seek shareholder authorization for the application of the initial public offering of overseas listed shares (H-shares) [3]. - The specific details regarding the H-share issuance and listing have not yet been finalized [1].

新诺威（300765）(300765.SZ)公告，公司董事会及监事会于2025年9月30日审议通过关于提请股东大会 授权董事会及其获授权人士全权办理公司申请首次公开发行境外上市股份(H股)并在香港联合交易所有 限公司("香港联交所")主板上市有关事项等相关议案("本次发行H股并上市")。 ...

Core Viewpoint - The company, XinNuoWei (300765.SZ), is advancing its globalization strategy by planning to apply for an initial public offering (IPO) of overseas listed shares (H-shares) on the Hong Kong Stock Exchange to enhance its core competitiveness in international markets and promote the development of its pharmaceutical business [1] Group 1 - The company will hold the 26th meeting of the sixth board of directors and the 21st meeting of the sixth supervisory board on September 30, 2025, to review and approve the proposal for the IPO [1] - The decision aims to create an international capital operation platform [1] - The initiative is part of the company's efforts to deepen its global strategic layout [1]

（记者 曾健辉） 每经头条（nbdtoutiao）——前脚消费贷，后脚被银行追讨发票，7天内上传，否则后果严重！有人为此 焦虑，有人却趁机牟利：帮开票包过审 每经AI快讯，新诺威9月30日晚间发布公告称，公司第六届第二十六次董事会会议于2025年9月30日在 公司会议室以现场加通讯表决相结合的方式召开。会议审议了《关于修订 <董事会审计委员会工作细则 > 的议案》等文件。 ...

Core Viewpoint - The company, XinNuoWei, announced plans to apply for an initial public offering (IPO) of overseas listed shares (H-shares) and to list on the main board of the Hong Kong Stock Exchange [1] Group 1 - The sixth board of directors and the sixth supervisory board of the company will hold meetings on September 30, 2025, to review and approve the proposal for the IPO [1]

Core Viewpoint - The company plans to apply for an initial public offering (IPO) of overseas listed shares (H-shares) to enhance its global strategy, improve international market competitiveness, and promote the development of its pharmaceutical business [1] Group 1: IPO Plans - The company aims to create an international capital operation platform through the proposed H-share IPO [1] - The IPO will be submitted for approval at a shareholders' meeting and requires regulatory approvals from relevant government and regulatory bodies [1] - The company will consider the interests of existing shareholders and market conditions to choose an appropriate timing for the H-share issuance and listing [1] Group 2: Uncertainties and Disclosure - Specific details regarding the IPO are not yet finalized, indicating significant uncertainties surrounding the matter [1] - The company commits to fulfilling its information disclosure obligations as the situation develops [1]

南财智讯9月30日电，新诺威公告，为深入推进全球化战略布局，打造国际化资本运作平台，提高公司 在国际市场的核心竞争力，促进公司成药业务的发展，公司拟发行H股并在香港联合交易所有限公司上 市。2025年9月30日，公司召开第六届董事会第二十六次会议、第六届监事会第二十一次会议，审议通 过了相关议案。本次发行H股并上市还需提交公司股东大会审议，并需取得中国证券监督管理委员会、 香港联交所和香港证券及期货事务监察委员会等相关政府机构、监管机构的备案、批准和/或核准。 ...

石药创新制药股份有限公司 独立董事专门会议工作制度 第一条 为维护石药创新制药股份有限公司（以下简称"公司"）的法人治理，充分 发挥独立董事在公司治理中的作用，根据《中华人民共和国公司法》（以下简称"《公司 法》")《上市公司治理准则》《上市公司独立董事管理办法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》《石药创新制药股份有限公司章程》（"以下简称《公司章程》"）《石药创新制药股 份有限公司独立董事工作细则》及其他有关规定并结合公司实际情况，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与其所受聘的公司及 其主要股东、实际控制人不存在直接或间接利害关系，或者其他可能影响其进行独立客 观判断关系的董事。 第五条 独立董事专门会议可以采取通讯表决的方式召开；半数以上独立董事提议 可以召开临时会议。 第六条 独立董事专门会议应由全部独立董事出席方可举行，独立董事应当亲自出 席独立董事专门会议，因故不能亲自出席会议的，应当事先审阅会议材料，形成明确的 意见，并书面委托其他独立董事代为出席。 第七条 独立董事专门会议由过半数独 ...